Axogen, Inc. (AXGN) has a MoatMap StockRank of 91/100 based on Quality (60/100), Value (35/100), and Momentum (80/100) factor scores. The current signal is STRONG BUY. Axogen is a niche medical technology company focused on peripheral nerve repair; it does not fit our CDMO pricing power theme or any other active macro thesis.
Axogen, Inc. is a leading medical technology company dedicated to the science of peripheral nerve repair and regeneration. The company's competitive moat is established by its comprehensive, clinically validated portfolio of nerve grafts and connectors, which are widely adopted by microsurgeons. It operates as the dominant market leader in the niche peripheral nerve reconstruction space, supported by extensive intellectual property and clinical data.
| Price | $42.39 |
| Market Cap | $2.1B |
| P/E (Forward) | 58.20 |
| Price/Book | 9.20 |
| Return on Equity | -18.0% |
| Return on Invested Capital | -4.0% |
| Debt/Equity | 8.43 |
| Gross Margin | 75.0% |
| Operating Margin | -4.6% |
| Revenue Growth | 26.6% |
| Free Cash Flow | $18M |
Axogen, Inc. operates in the Medical Devices industry, part of the Healthcare sector (United States).